Overview

Drug Use Investigation for IMIGRAN Tablet

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The study is designed to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy of sumatriptan tablet, and to discuss the need of special investigation and postmarketing clinical study. A special focus was placed on the investigation of occurrence of "ischaemic heart disease-like events including arrhythmia, angina pectoris, and myocardial infarction" in the present study.
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Sumatriptan